TMB-001 is intended for the treatment of congenital ichthyosis, a rare skin condition. Credit: Kwangmoozaa / Shutterstock.com.

Leo Pharma has entered an agreement for the acquisition of US-based clinical-stage biopharma firm Timber Pharmaceuticals for $36m. 

Timber develops and markets therapies to treat rare and orphan dermatologic conditions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal comprises an initial upfront payment of $14m followed by $22m in contingent value rights on meeting specified future milestones.

Leo will bolster its medical dermatology pipeline by gaining rights to a late-stage investigational product candidate of Timber, TMB-001. 

TMB-001 is a new formulation of the active ingredient isotretinoin for topical use. It is intended for the treatment of congenital ichthyosis, a rare skin condition.

See Also:

The US Food and Drug Administration (FDA) previously granted orphan and breakthrough designations for the asset. A decision on approval is anticipated in 2025. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TMB-001 demonstrated positive results in a Phase II clinical trial. Recruitment for a Phase III study is underway in Europe and the US.

Leo Pharma CEO Christophe Bourdon stated: “Signing an agreement to acquire Timber Pharmaceuticals and TMB-001, which is still subject to certain closing conditions, is an additional step in delivering on our strategy. 

“We will add an attractive late-stage asset to our medical dermatology pipeline and strengthen our team in the US. 

“And most importantly, we will add an asset with a promising outlook to be able to help patients suffering from a debilitating disease who today have no proper treatment options.”

The deal will be concluded in the fourth quarter of 2023.